Design optimization for clinical trials in early-stage manifest Huntington's disease-Reference-Cited by-同舟云学术

Design optimization for clinical trials in early-stage manifest Huntington's disease

Published:2017-09-14 Issue:11 Volume:32 Page:1610-1619
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Frost Chris¹,Mulick Amy¹,Scahill Rachael I.²,Owen Gail²,Aylward Elizabeth³,Leavitt Blair R.⁴,Durr Alexandra⁵⁶,Roos Raymund A. C.⁷,Borowsky Beth⁸⁹,Stout Julie C.¹⁰,Reilmann Ralf¹¹¹²¹³,Langbehn Douglas R.¹⁴,Tabrizi Sarah J.²,Sampaio Cristina⁸,

Affiliation:

1. Department of Medical Statistics; London School of Hygiene and Tropical Medicine; London UK

2. Huntington's Disease Centre, UCL Institute of Neurology; Department of Neurodegenerative Disease, University College London; London UK

3. Center for Integrative Brain Research; Seattle Children's Research Institute; Seattle Washington USA

4. Department of Medical Genetics; University of British Columbia; Vancouver British Columbia Canada

5. Brain and Spine Institute, INSERM U1127, Centre National de la Recherche Scientifique, UMR7225; Sorbonne Universités, University Pierre and Marie Curie, Paris VI UMR_S1127; Paris France

6. Assistance Publique - Hôpitaux de Paris, Genetic Department; Pitié -Salpêtrière University Hospital; Paris France

7. Department of Neurology; Leiden University Medical Centre; Leiden The Netherlands

8. CHDI Management, CHDI Foundation; Princeton New Jersey USA

9. Clinical Development, Neurodegenerative Diseases; Teva Pharmaceuticals; Malvern Pennsylvania USA

10. School of Psychological Sciences; Monash University; Melbourne Victoria Australia

11. George Huntington Institute; Muenster Germany

12. Institute for Clinical Radiology; University of Muenster; Muenster Germany

13. Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research; University of Tuebingen; Tuebingen Germany

14. Department of Psychiatry; University of Iowa; Iowa City Iowa USA

Funder

Cure Huntington’s Disease Initiative (CHDI)

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference36 articles.

1. Therapeutic interventions for disease progression in Huntington's disease;Mestre;Cochrane Database Syst Rev,2009

2. Clinical trials in Huntington's disease: interventions in early clinical development and newer methodological approaches;Sampaio;Mov Disord,2014

3. Modelling and simulation in the pharmaceutical industry-some reflections;Burman;Pharm Stat,2011

4. Critical Path Institute U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute's Clinical Trial Simulation Tool for Alzheimer's Disease 2013 http://c-path.org/wp-content/uploads/2014/03/US-FDA-EMA-agency-reach-landmark-decisions-C-Path-clinical-trial-simulation-tool-for-alzheimers-disease.pdf

5. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data;Tabrizi;Lancet Neurol,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group;Journal of Huntington's Disease;2024-07-02

2. How important is the linearity assumption in a sample size calculation for a randomised controlled trial where treatment is anticipated to affect a rate of change?;BMC Medical Research Methodology;2023-11-21

3. Heterogeneity in Preclinical Alzheimer’s Disease Trial Cohort Identified by Image-based Data-Driven Disease Progression Modelling;2023-02-10

4. Neuroimaging Biomarkers for Huntington’s Disease;From Pathophysiology to Treatment of Huntington's Disease;2022-10-26

5. Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review;Frontiers in Neurology;2021-09-21